Clinical Trials and Research

AbstractBACKGROUND Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare and fatal cardiomyopathy resulting from myocardial deposition of misfolded transthyretin…

AbstractBackground: Acoramidis, an oral transthyretin stabilizer that achieves near-complete (≥90%) transthyretin stabilization, demonstrated significant clinical…

AbstractCardiac amyloidosis (CA) is a progressive infiltrative cardiomyopathy most commonly caused by transthyretin (ATTR) or immunoglobulin light chain (AL)…

Transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive disease characterized by the accumulation of misfolded transthyretin amyloid proteins in the…

AbstractIntroductionTimely diagnosis and treatment are essential for improving outcomes and quality of life in patients with transthyretin (ATTR) amyloidosis. Early…

Medison Pharma’s Amvuttra (vutrisiran) has entered Korea’s reimbursement system for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), raising…

AbstractAcute heart failure (AHF) represents a major global health challenge, with a substantial impact on survival, morbidity, and health care resource utilization…

AbstractBACKGROUND:Cardiac amyloidosis (CA) is an underdiagnosed yet treatable cause of heart failure in which timely diagnosis is essential to initiate life-…

AbstractBackground and ObjectiveWe assessed the consistency of serum transthyretin (TTR) knockdown with the RNA interference therapeutic vutrisiran across…

AbstractSystemic amyloid light-chain (AL) amyloidosis is a multisystem disorder caused by extracellular deposition of monoclonal immunoglobulin light chains.…